Immunorestoration in children with recurrent respiratory infections treated with isoprinosine.
In 27 children, 4-8 years old, with recurrent respiratory infections of the upper and lower respiratory tracts Isoprinosine (ISO) tablets were administered for 7-10 days at daily doses of 50-100 mg/kg. Clinical signs of acute respiratory disease, including temperature abnormalities and subjective complaints, subsided in a short time and the children showed no symptoms for periods ranging from several weeks to several months following the therapy. The children were selected for immunotherapy with ISO on the basis of their low levels of E-rosette forming cells in peripheral blood. Several immune function parameters assessed immediately after treatment with ISO and compared with those obtained before illness and ISO administration. Low levels of T-lymphocytes returned to normal after ISO therapy, B-lymphocyte relative and absolute numbers, however, were not affected by the treatment. Nor were any changes due to ISO found in immunoglobulins, complement components, beta 2-microglobulin and C-reactive protein. Moreover, ISO had no stimulative effect on spontaneous tetrazolium reductase activity of granulocytes but it showed a slight inhibition of their phagocytosis-associated metabolic activity.
D002648:Child; D002675:Child, Preschool; D005260:Female; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D007958:Leukocyte Count; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology; D008297:Male; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D007288:Inosine; D007542:Inosine Pranobex